HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.
LPI (LP Information)' newest research report, the “Hepatocellular Carcinoma Drugs Industry Forecast” looks at past sales and reviews total world Hepatocellular Carcinoma Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Hepatocellular Carcinoma Drugs sales for 2023 through 2029. With Hepatocellular Carcinoma Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hepatocellular Carcinoma Drugs industry.
This Insight Report provides a comprehensive analysis of the global Hepatocellular Carcinoma Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hepatocellular Carcinoma Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hepatocellular Carcinoma Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatocellular Carcinoma Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatocellular Carcinoma Drugs.
The global Hepatocellular Carcinoma Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.
This report presents a comprehensive overview, market shares, and growth opportunities of Hepatocellular Carcinoma Drugs market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Brachytherapy
Chemotherapy
Local Ablation Therapy
Segmentation by application
Hospitals
Clinics
Cancer Rehabilitation Centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Eli Lilly
Johnson and Johnson
Pfizer
Bristol-Myers Squibb
Celgene
F. Hoffmann-la Roche
Gilead
GlaxoSmithKline
Merck
Novartis

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Hepatocellular Carcinoma Drugs Market Size 2018-2029 2.1.2 Hepatocellular Carcinoma Drugs Market Size CAGR by Region 2018 VS 2022 VS 2029 2.2 Hepatocellular Carcinoma Drugs Segment by Type 2.2.1 Brachytherapy 2.2.2 Chemotherapy 2.2.3 Local Ablation Therapy 2.3 Hepatocellular Carcinoma Drugs Market Size by Type 2.3.1 Hepatocellular Carcinoma Drugs Market Size CAGR by Type (2018 VS 2022 VS 2029) 2.3.2 Global Hepatocellular Carcinoma Drugs Market Size Market Share by Type (2018-2023) 2.4 Hepatocellular Carcinoma Drugs Segment by Application 2.4.1 Hospitals 2.4.2 Clinics 2.4.3 Cancer Rehabilitation Centers 2.5 Hepatocellular Carcinoma Drugs Market Size by Application 2.5.1 Hepatocellular Carcinoma Drugs Market Size CAGR by Application (2018 VS 2022 VS 2029) 2.5.2 Global Hepatocellular Carcinoma Drugs Market Size Market Share by Application (2018-2023) 3 Hepatocellular Carcinoma Drugs Market Size by Player 3.1 Hepatocellular Carcinoma Drugs Market Size Market Share by Players 3.1.1 Global Hepatocellular Carcinoma Drugs Revenue by Players (2018-2023) 3.1.2 Global Hepatocellular Carcinoma Drugs Revenue Market Share by Players (2018-2023) 3.2 Global Hepatocellular Carcinoma Drugs Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Hepatocellular Carcinoma Drugs by Regions 4.1 Hepatocellular Carcinoma Drugs Market Size by Regions (2018-2023) 4.2 Americas Hepatocellular Carcinoma Drugs Market Size Growth (2018-2023) 4.3 APAC Hepatocellular Carcinoma Drugs Market Size Growth (2018-2023) 4.4 Europe Hepatocellular Carcinoma Drugs Market Size Growth (2018-2023) 4.5 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size Growth (2018-2023) 5 Americas 5.1 Americas Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) 5.2 Americas Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) 5.3 Americas Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Hepatocellular Carcinoma Drugs Market Size by Region (2018-2023) 6.2 APAC Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) 6.3 APAC Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Hepatocellular Carcinoma Drugs by Country (2018-2023) 7.2 Europe Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) 7.3 Europe Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Hepatocellular Carcinoma Drugs by Region (2018-2023) 8.2 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) 8.3 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Hepatocellular Carcinoma Drugs Market Forecast 10.1 Global Hepatocellular Carcinoma Drugs Forecast by Regions (2024-2029) 10.1.1 Global Hepatocellular Carcinoma Drugs Forecast by Regions (2024-2029) 10.1.2 Americas Hepatocellular Carcinoma Drugs Forecast 10.1.3 APAC Hepatocellular Carcinoma Drugs Forecast 10.1.4 Europe Hepatocellular Carcinoma Drugs Forecast 10.1.5 Middle East & Africa Hepatocellular Carcinoma Drugs Forecast 10.2 Americas Hepatocellular Carcinoma Drugs Forecast by Country (2024-2029) 10.2.1 United States Hepatocellular Carcinoma Drugs Market Forecast 10.2.2 Canada Hepatocellular Carcinoma Drugs Market Forecast 10.2.3 Mexico Hepatocellular Carcinoma Drugs Market Forecast 10.2.4 Brazil Hepatocellular Carcinoma Drugs Market Forecast 10.3 APAC Hepatocellular Carcinoma Drugs Forecast by Region (2024-2029) 10.3.1 China Hepatocellular Carcinoma Drugs Market Forecast 10.3.2 Japan Hepatocellular Carcinoma Drugs Market Forecast 10.3.3 Korea Hepatocellular Carcinoma Drugs Market Forecast 10.3.4 Southeast Asia Hepatocellular Carcinoma Drugs Market Forecast 10.3.5 India Hepatocellular Carcinoma Drugs Market Forecast 10.3.6 Australia Hepatocellular Carcinoma Drugs Market Forecast 10.4 Europe Hepatocellular Carcinoma Drugs Forecast by Country (2024-2029) 10.4.1 Germany Hepatocellular Carcinoma Drugs Market Forecast 10.4.2 France Hepatocellular Carcinoma Drugs Market Forecast 10.4.3 UK Hepatocellular Carcinoma Drugs Market Forecast 10.4.4 Italy Hepatocellular Carcinoma Drugs Market Forecast 10.4.5 Russia Hepatocellular Carcinoma Drugs Market Forecast 10.5 Middle East & Africa Hepatocellular Carcinoma Drugs Forecast by Region (2024-2029) 10.5.1 Egypt Hepatocellular Carcinoma Drugs Market Forecast 10.5.2 South Africa Hepatocellular Carcinoma Drugs Market Forecast 10.5.3 Israel Hepatocellular Carcinoma Drugs Market Forecast 10.5.4 Turkey Hepatocellular Carcinoma Drugs Market Forecast 10.5.5 GCC Countries Hepatocellular Carcinoma Drugs Market Forecast 10.6 Global Hepatocellular Carcinoma Drugs Forecast by Type (2024-2029) 10.7 Global Hepatocellular Carcinoma Drugs Forecast by Application (2024-2029) 11 Key Players Analysis 11.1 Bayer 11.1.1 Bayer Company Information 11.1.2 Bayer Hepatocellular Carcinoma Drugs Product Offered 11.1.3 Bayer Hepatocellular Carcinoma Drugs Revenue, Gross Margin and Market Share (2018-2023) 11.1.4 Bayer Main Business Overview 11.1.5 Bayer Latest Developments 11.2 Eli Lilly 11.2.1 Eli Lilly Company Information 11.2.2 Eli Lilly Hepatocellular Carcinoma Drugs Product Offered 11.2.3 Eli Lilly Hepatocellular Carcinoma Drugs Revenue, Gross Margin and Market Share (2018-2023) 11.2.4 Eli Lilly Main Business Overview 11.2.5 Eli Lilly Latest Developments 11.3 Johnson and Johnson 11.3.1 Johnson and Johnson Company Information 11.3.2 Johnson and Johnson Hepatocellular Carcinoma Drugs Product Offered 11.3.3 Johnson and Johnson Hepatocellular Carcinoma Drugs Revenue, Gross Margin and Market Share (2018-2023) 11.3.4 Johnson and Johnson Main Business Overview 11.3.5 Johnson and Johnson Latest Developments 11.4 Pfizer 11.4.1 Pfizer Company Information 11.4.2 Pfizer Hepatocellular Carcinoma Drugs Product Offered 11.4.3 Pfizer Hepatocellular Carcinoma Drugs Revenue, Gross Margin and Market Share (2018-2023) 11.4.4 Pfizer Main Business Overview 11.4.5 Pfizer Latest Developments 11.5 Bristol-Myers Squibb 11.5.1 Bristol-Myers Squibb Company Information 11.5.2 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Product Offered 11.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Revenue, Gross Margin and Market Share (2018-2023) 11.5.4 Bristol-Myers Squibb Main Business Overview 11.5.5 Bristol-Myers Squibb Latest Developments 11.6 Celgene 11.6.1 Celgene Company Information 11.6.2 Celgene Hepatocellular Carcinoma Drugs Product Offered 11.6.3 Celgene Hepatocellular Carcinoma Drugs Revenue, Gross Margin and Market Share (2018-2023) 11.6.4 Celgene Main Business Overview 11.6.5 Celgene Latest Developments 11.7 F. Hoffmann-la Roche 11.7.1 F. Hoffmann-la Roche Company Information 11.7.2 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Product Offered 11.7.3 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Revenue, Gross Margin and Market Share (2018-2023) 11.7.4 F. Hoffmann-la Roche Main Business Overview 11.7.5 F. Hoffmann-la Roche Latest Developments 11.8 Gilead 11.8.1 Gilead Company Information 11.8.2 Gilead Hepatocellular Carcinoma Drugs Product Offered 11.8.3 Gilead Hepatocellular Carcinoma Drugs Revenue, Gross Margin and Market Share (2018-2023) 11.8.4 Gilead Main Business Overview 11.8.5 Gilead Latest Developments 11.9 GlaxoSmithKline 11.9.1 GlaxoSmithKline Company Information 11.9.2 GlaxoSmithKline Hepatocellular Carcinoma Drugs Product Offered 11.9.3 GlaxoSmithKline Hepatocellular Carcinoma Drugs Revenue, Gross Margin and Market Share (2018-2023) 11.9.4 GlaxoSmithKline Main Business Overview 11.9.5 GlaxoSmithKline Latest Developments 11.10 Merck 11.10.1 Merck Company Information 11.10.2 Merck Hepatocellular Carcinoma Drugs Product Offered 11.10.3 Merck Hepatocellular Carcinoma Drugs Revenue, Gross Margin and Market Share (2018-2023) 11.10.4 Merck Main Business Overview 11.10.5 Merck Latest Developments 11.11 Novartis 11.11.1 Novartis Company Information 11.11.2 Novartis Hepatocellular Carcinoma Drugs Product Offered 11.11.3 Novartis Hepatocellular Carcinoma Drugs Revenue, Gross Margin and Market Share (2018-2023) 11.11.4 Novartis Main Business Overview 11.11.5 Novartis Latest Developments 12 Research Findings and Conclusion